Articles

The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia

1Department of Pediatric Oncology/Hematology, Erasmus MC Rotterdam-Sophia Children’s Hospital, Rotterdam, the Netherlands
2Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA;3NCI-FDA Clinical Proteomics Program, Food and Drug Administration, Bethesda, MD, USA
1Department of Pediatric Oncology/Hematology, Erasmus MC Rotterdam-Sophia Children’s Hospital, Rotterdam, the Netherlands
2Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA
1Department of Pediatric Oncology/Hematology, Erasmus MC Rotterdam-Sophia Children’s Hospital, Rotterdam, the Netherlands
1Department of Pediatric Oncology/Hematology, Erasmus MC Rotterdam-Sophia Children’s Hospital, Rotterdam, the Netherlands
1Department of Pediatric Oncology/Hematology, Erasmus MC Rotterdam-Sophia Children’s Hospital, Rotterdam, the Netherlands
4Dutch Childhood Oncology Group (DCOG), the Hague, the Netherlands;5Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, the Netherlands
4Dutch Childhood Oncology Group (DCOG), the Hague, the Netherlands;6Department of Pediatric Oncology, University of Groningen-Beatrix Children’s Hospital, Groningen, the Netherlands
7German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia (COALL), Hamburg, Germany;8Research Institute Children's Cancer Center Hamburg, Clinic of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
1Department of Pediatric Oncology/Hematology, Erasmus MC Rotterdam-Sophia Children’s Hospital, Rotterdam, the Netherlands
1Department of Pediatric Oncology/Hematology, Erasmus MC Rotterdam-Sophia Children’s Hospital, Rotterdam, the Netherlands
Vol. 97 No. 9 (2012): September, 2012 https://doi.org/10.3324/haematol.2011.059030